Brought to you by 
Pacific Biosciences nets $186mm via its IPO
27 Apr 2012
Executive Summary
Just two months after filing, Pacific Biosciences of California Inc. (PacBio; tools for synthesis and regulation of DNA, RNA, and proteins) has completed its initial public offering, becoming the first US life sciences company to go public this year. PacBio sold 12.5mm common shares at $16 each (the mid-point of its proposed price range), netting $186mm.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pacific Biosciences nets $186mm via its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice